| Title | A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234 |
| Protocole ID | IND.234C |
| ClinicalTrials.gov ID | NCT03385655 |
| Cancer Type(s) | Prostate |
| Phase | Phase II |
| Stage | |
| Study Type | |
| Drug | Darolutamide (ODM-201) |
| Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
| City | Montréal |
| Principal Investigator |
Dr. Fred Saad |
| Coordinator |
Amal Nadiri 514-890-8000 poste 26074 |
| Status | Recruiting |
| Activation Date | |
| Eligibility Criteria |
Patients must meet the following criteria in addition to the eligiblity criteria outlined in IND.234.
|
| Exclusion Criteria | |
Groupe d'étude en oncologie du Québec